Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 84

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 84
---
 IIA grants, the terms of these grants and the Research Law restrict the transfer or license of such know-how, and the transfer
of manufacturing or manufacturing rights of such products, technologies or know-how outside of Israel, without the prior approval of
the IIA. Therefore, the discretionary approval of an IIA committee would be required for any transfer or license to third parties inside
or outside of Israel of know-how or for the transfer outside of Israel of manufacturing or manufacturing rights related to those aspects
of such technologies. We may not receive those approvals. Furthermore, the IIA may impose certain conditions on any arrangement under
which it permits us to transfer technology or development.

The transfer or license of
IIA-supported technology or know-how outside of Israel and the transfer of manufacturing of IIA-supported products, technology or know-how
outside of Israel may involve the payment of significant amounts, depending upon the value of the transferred or licensed technology
or know-how, our research and development expenses, the amount of IIA support, the time of completion of the IIA-supported research project
and other factors. These restrictions and requirements for payment may impair our ability to sell, license or otherwise transfer our
technology assets outside of Israel or to outsource or transfer development or manufacturing activities with respect to any product or
technology outside of Israel. Furthermore, the consideration available to our shareholders in a transaction involving the transfer outside
of Israel of technology or know-how developed with IIA funding (such as a merger or similar transaction) may be reduced by any amounts
that we are required to pay to the IIA. The terms and conditions of the IIA grants may require that a company which ceases the development
of know-how, technology or products using IIA grants not due to a failure of such development activities, be required to repay such amount
of grants, which in our case, amount to $2.6 million (including interest at the amount of $0.3 million).

We may not be able to enforce covenants not-to-compete under current Israeli law that might result in added competition for our products.

We have non-competition agreements
with all of our employees and executive officers all of which are governed by Israeli law. These agreements prohibit our employees from
competing with or working for our competitors, generally during their employment and for up to 12 months after termination of their employment.
However, Israeli courts are reluctant to enforce non-compete undertakings of former employees and tend, if at all, to enforce those